FDA granted Fast Track Designation to BioInvent's BI-1808.
2 reports, 1 independent
Updated Aug 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Fast Track Designation to BioInvent's BI-1808.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- SBE303 received Fast Track designation from the FDA, involving the African Democratic Congress.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- FDA granted Fast Track designation while PTC Therapeutics and Eli Lilly acquired assets from Sangamo Therapeutics.
- Congress and the Senate are considering legislation affecting FDA submissions and drug patent rights.
- FDA accepts a BLA for biosimilar review and extends its review process to Health Canada.